ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.
 PMID: 15980328       2005       Antimicrobial agents and chemotherapy
Abstract: The major mechanism of resistance has been attributed to the alteration in the YMDD motif of the HBV polymerase due to an amino acid change of rtM204 to V/I and an accompanying rtL180M conversion.
Abstract: The resistance profile was comparable to that of the previously reported rtL180 M/M204I-containing virus.


  Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
 PMID: 15985011       2005       Journal of viral hepatitis
Abstract: YMDD mutation at rtL180M and rtM204V/I measured by restriction digest of amplified products.


  Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
 PMID: 16152756       2005       Antiviral therapy
Abstract: To investigate this in vitro, we generated novel stable cell lines expressing HBV encoding the four major patterns of lamivudine resistance mutations (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I and rtL180M+ rtM204I).


  Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
 PMID: 16197491       2005       Alimentary pharmacology & therapeutics
Abstract: The L180M substitution was detected in four of eight (50%) of group A and in none of groups B1 and B2.


  Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
 PMID: 16218172       2005       Antiviral therapy
Abstract: Phenotypic analyses revealed that constructs harbouring rtA194T combined with rtL180M and rtM204V displayed an over 10-fold increase in the IC50 for TDF compared with the wild type.


  Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays.
 PMID: 16220028       2005       Le infezioni in medicina
Abstract: affigene HBV mutant VL (positions G1764A, G1896A) and affigene HBV DE/3TC (positions rtL180M, rtM204V/I) were able to detect a low presence of mutants in a mixed population (wild type and mutant) compared to direct sequencing and Inno-LIPA HBV DR, which identified only the dominant population.


  Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment.
 PMID: 16314804       2005       Transplantation
Abstract: Lamivudine treatment was initially effective in all patients; three patients during the second year of treatment developed lamivudine resistance-associated mutations (rt-L180M, rt-M204V) with severe disease reactivation, remitted after switch to adefovir treatment.


  Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.
 PMID: 16358376       2005       Journal of Zhejiang University. Science. B
Abstract: Four types of YMDD mutation were observed in this study, rtL180M/M204V mutation was the predominant type (26/63, 41.3%).


  In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
 PMID: 15259898       2004       Antiviral therapy
Abstract: Although all patients responded to ADV in this clinical study, the serum HBV reduction was lower in the seven patients with the triple mutation (median -3.3 log copies/ml) compared to the patients who had only the rtL180M/M204V mutations (median -4.1 log copies/ml) at week 48 (P=0.04, Mann-Whitney test).
Abstract: For ADV and TDF, comparison of wild-type and lamivudine-resistant HBV IC50 (rtL180M-M204V) showed, respectively, 2.85-fold (from 0.07 to 0.2 microM) and 3.3-fold (from 0.06 to 0.2 microM) increases, indicating a mild decrease of both drug activities, in vitro.
Abstract: In a clinical study of ADV (Gilead 460i study), seven of the 35 patients carried HBV strains with the triple lamivudine resistance-associated amino-acid changes  PMID: 15261293       2004       Bioorganic & medicinal chemistry letters
Abstract: Molecular modeling studies of adefovir diphosphate with the wild type and the mutant HBV polymerase-DNA complex demonstrated that the increase in adefovir sensitivity toward HBV polymerase mutants (rtL180M, rtM204V/I, rtL180M-M204V/I) is a result of increased van der Waals interaction and is supplemented by the decreased affinity of natural substrate toward the mutant HBV polymerase.



Browser Board

 Co-occurred Entities




   Filtrator